Bergamo Lymphoid Cancer Registry

NCT ID: NCT03131531

Last Updated: 2024-03-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

6000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-03-23

Study Completion Date

2037-03-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Lymphoid cancer including Hodgkin disease, non-Hodgkin lymphomas (NHL) and myeloma, represents the most common hematologic malignancy. Despite the overall prognosis improved in the last 10 years, there are many open issues that need to be addressed, specifically refractoriness to standard treatment, disease recurrence and outcome with new drug in the so called "real world" setting. Since the Hematology and Bone Marrow Transplant Unit at "Ospedale Papa Giovanni XIII" of Bergamo has developed specific tools to collect clinical data thought fully validated electronic charts and biological specimens thanks to a regulatory compliant biobanking program, the aim of this study is to collect clinical and biological information of lymphoid cancer patients. The cohort of patients enrolled will permit to analyze the practice pattern, perform biological correlative studies of great translational potential with relevance to clinical practice.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hodgkin Lymphoma Non Hodgkin Lymphoma Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hodgkin lymphoma

Patient registry

Intervention Type OTHER

Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures

Non-Hodgkin lymphoma

Patient registry

Intervention Type OTHER

Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures

Myeloma

Patient registry

Intervention Type OTHER

Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Patient registry

Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients 18 years or older
* Written informed consent
* Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma

Exclusion Criteria

\- Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

A.O. Ospedale Papa Giovanni XXIII

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rambaldi Alessandro

Prof.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alessandro Rambaldi, MD

Role: PRINCIPAL_INVESTIGATOR

A.O. Ospedale Papa Giovanni XXIII

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hematology and Bone Marrow Transplant Unit, A.O. Ospedale Papa Giovanni XXIII

Bergamo, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Alessandro Rambaldi, MD

Role: CONTACT

+39.035.2673683

Giuseppe Gritti, MD, PhD

Role: CONTACT

+39.035.2673679

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Giuseppe Gritti, MD, PhD

Role: primary

+39.035.2673684

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BLCR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AGMT Austrian Lymphoma Registry
NCT06294652 RECRUITING